The nod is subject to amendment in how primary efficacy endpoint for symptomatic cases be studied in Phase 3 trials, the panel further stated.
source https://www.hindustantimes.com/india-news/covaxin-bharat-biotech-gets-nod-from-dcgi-panel-for-phase-iii-trials/story-FtYixQLYpGdPcdYkpclnMP.html
No comments:
Post a Comment